Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy
Status:
Terminated
Trial end date:
2016-08-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to see whether PRO045 is safe and effective to use as medication
for Duchenne Muscular Dystrophy (DMD) patients with a mutation around location 45 in the DNA
for the dystrophin protein.